transparent gif


Ej inloggad.

Göteborgs universitets publikationer

The societal cost of bipolar disorder in Sweden

Författare och institution:
M. Ekman (-); O. Granstrom (-); S. Omerov (-); J. Jacob (-); Mikael Landén (Institutionen för neurovetenskap och fysiologi)
Publicerad i:
Social Psychiatry and Psychiatric Epidemiology, 48 ( 10 ) s. 1601-1610
Artikel, refereegranskad vetenskaplig
Sammanfattning (abstract):
There is a lack of comprehensive cost-of-illness studies in bipolar disorder, in particular studies based on patient-level data. The purpose of this study was to estimate the societal cost of bipolar disorder and to relate costs to disease severity, depressive episodes, hospitalisation and patient functioning. Retrospective resource use data in inpatient and outpatient care during 2006-2008, as well as ICD-10 diagnoses and Global Assessment of Functioning (GAF) scores, were obtained from the Northern Stockholm psychiatric clinic with a catchment area including 47 % of the adult inhabitants in Stockholm. This dataset was combined with national register data on prescription pharmaceuticals and sick leave to estimate the societal cost of bipolar disorder. The study was conducted from a societal perspective, with indirect costs valued according to the human capital method. The average annual cost per patient was a,not sign28,011 in 2008 (n = 1,846). Indirect costs due to sick leave and early retirement represented 75 %, inpatient costs 13 %, outpatient costs 8 %, pharmaceuticals 2 % and community care another 2 % of the total cost. Total costs were considerably higher during mood episodes (six times higher than in remission), for hospitalised patients (a,not sign55,500 vs. a,not sign22,200) and for patients with low GAF scores. The high cost of bipolar disorder is driven primarily by indirect costs. Costs were strongly associated with mood episodes, hospitalisations and low GAF scores. This suggests that treatment that reduces the risk for relapses and hospitalizations and improve functioning may decrease both the societal cost of bipolar disorder and patient suffering.
Ämne (baseras på Högskoleverkets indelning av forskningsämnen):
Klinisk medicin
Bipolar affective disorder, Economics, Cost, Burden-of-illness, Resource use, MANIC EPISODES, DOUBLE-BLIND, OF-ILLNESS, PREVALENCE, OLANZAPINE, QUETIAPINE, ISSUES
Postens nummer:
Posten skapad:
2013-11-04 14:17

Visa i Endnote-format

Göteborgs universitet • Tel. 031-786 0000
© Göteborgs universitet 2007